Gilead Sciences Inc.
Gilead Sciences Reports Q1 2025 Financial Results
Summary
Gilead Sciences, Inc. reported its first quarter 2025 financial results, showing flat total revenues of $6.7 billion. Diluted earnings per share (EPS) were $1.04 compared to a loss of $3.34 in the same period of 2024. The company's base business grew 4% year-over-year, primarily driven by Biktarvy's strength. Gilead also announced several clinical trial updates and regulatory milestones, including FDA acceptance of a New Drug Application for lenacapavir for HIV prevention. Non-GAAP diluted EPS was $1.81, reflecting prior year charges that did not repeat.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement